Get the Stockscreener App
0.4383
6.76%
-0.0318
Pre-market:
.41
-0.0283
-6.45%
Equillium Inc stock is traded at $0.4383, with a volume of 66,992.
It is down -6.76% in the last 24 hours and down -44.94% over the past month.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
See More
Previous Close:
$0.47
Open:
$0.442
24h Volume:
66,992
Relative Volume:
0.09
Market Cap:
$16.26M
Revenue:
$45.91M
Net Income/Loss:
$-4.62M
P/E Ratio:
-3.1259
EPS:
-0.1402
Net Cash Flow:
$-21.51M
1W Performance:
-7.25%
1M Performance:
-44.94%
6M Performance:
-62.86%
1Y Performance:
-75.79%
1-Day Range:
$0.43
$0.46
1-Week Range:
$0.413
$0.488
52-Week Range:
$0.3642
$1.89
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
0.4383 | 16.26M | 45.91M | -4.62M | -21.51M | -0.1402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
FDA declines itolizumab accelerated approval, says Equillium - The Pharma Letter
Equillium shares fall following FDA feedback By Investing.com - Investing.com India
Equillium shares fall following FDA feedback - Investing.com Australia
Equillium Announces Feedback from the U.S. Food and Drug Adminis - GuruFocus
Equillium (EQ) Faces Setback as FDA Declines Accelerated Approva - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval By Investing.com - Investing.com Canada
Equillium (EQ) Faces FDA Setback for Itolizumab in Graft-versus-Host Disease Treatment | EQ Stock News - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval - Investing.com
Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire
Equillium (NASDAQ:EQ) Shares Down 3.7% – Here’s Why - Defense World
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st
Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World
Leerink Partners Reaffirms “Market Perform” Rating for Equillium (NASDAQ:EQ) - Defense World
Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World
Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq
Equillium stock tumbles on Phase 3 study results By Investing.com - Investing.com India
Equillium stock tumbles on Phase 3 study results - Investing.com
Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace
Equillium Reports 2024 Financials and Clinical Milestones - TipRanks
Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com
Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa
Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia
Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter
Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener
Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com
Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe
Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - Stock Titan
Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World
Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year? - Yahoo Finance
Equillium Stock Price, Quotes and Forecasts - Benzinga
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations - Marketscreener.com
Equillium stock rallies 26% on itolizumab study data - MSN
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27% - Simply Wall St
Leerink Partnrs Forecasts Stronger Earnings for Equillium - Defense World
Equillium (EQ) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock - Nasdaq
Healthy Upside Potential: Equillium Inc (EQ) - SETE News
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):